www.ascept-paganz.com

ASCEPT

AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS AND TOXICOLOGISTS

PAGANZ

Population Approach Group of Australia & New Zealand

100% PURE NEW ZEALAND
newzealand.com

Queenstown, New Zealand
25-29 November 2019

Joint scientific meeting

Shared horizons: Optimising drug response to improve patient outcomes

#ASCEPTPAGANZ2019

Program

Download the ASCEPT-PAGANZ 2019 Scientific Meeting app

The Event App by EventsAIR includes everything you need to know about the Joint Scientific Meeting including the program, symposia, speakers, abstracts, social program and venue. Use the app to build your own conference agenda and contact other delegates via the app.

Whether you have an Apple iOS or Android mobile device you can download **The Event App by EventsAIR** via your Apple iTunes or Google play account.

To download the app to your phone or tablet, scan the appropriate QR code below:

Android **Apple**

To download to your computer, laptop or other device, enter the following URL: https://expertevents.eventsair.com/attendeeapp/ascept-paganz-2019/ascept-paganz/

The first time you open the app, you will need to enter this code: **ascept-paganz**

Then, log in using either your account email address and the password you created OR the PIN emailed to you.

Please opt in when you download the app so that you are able to use all of the interactive features and send messages to other delegates.

Engage with @ASCEPT2019 on Twitter for your chance to win a cash prize

#ASCEPTPAGANZ2019 contest – $200 prize

#ASCEPTPAGANZSponsors contest – $200 prize

#ASCEPTPAGANZPhotos contest – $100 prize

Further information is available at the registration desk or via the meeting app.

Social Media Policy

Meeting attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's specific scientific result on any forum including social media. We respectfully ask that if you attend a presentation where a presenter has communicated that they do not wish to have their presentation commented on in the social media environment that you adhere to this request. If you are presenting preliminary or unpublished data, and do not wish the results to be broadcast, please use the following logo with your presentation asking the audience to refrain from posting your material. It should appear on the title slide or poster, and if you like, any slides you do not want posted or commented on, so that your audience recognises your request.

"I request that my presentation is not recorded, photographed, commented on or posted about on social media or in any other forum."

Thank you.

ARE YOU WONDERING WHAT TO DO NEXT?

Join us and make discoveries leading to new medicines:

- High-impact research
- World-renowned academics
- State-of-the-art facilities
- Industry engagement

Research themes:

- Cardiovascular pharmacology
- Drug design
- Lung health research
- Mechanopharmacology
- Neuropharmacology
- Personalised therapeutics
- Translational pharmacology
- Venom research

Undergraduate and graduate opportunities
Innovative post-graduate research programs
– including a new 'Enterprise' specialisation

CONTACT US FOR MORE INFORMATION
Associate Professor James Ziogas
Acting Head of Department
jamesz@unimelb.edu.au
http://go.unimelb.edu.au/f9tr

Department of Pharmacology and Therapeutics
School of Biomedical Sciences

THE UNIVERSITY OF MELBOURNE

Monday 25 November 2019

08:00 – 17:00	**Registration desk open**	
	7th Floor Pre-Function Space, QT Queenstown	
08:30 – 17:00	**Beginner Population Approach workshop (Pharmacometrics)**	**Intermediate Population Approach workshop (Pharmacometrics)**
	Room: Rees room, QT Queenstown	**Room:** Dart room, QT Queenstown
	Supported by	
17:00 – 17:45	**PAGANZ AGM**	
	Room: Rees room, QT Queenstown	
18:00 – 19:30	**ASCEPT Board meeting**	
	Room: Dart room, QT Queenstown	

Tuesday 26 November 2019

08:00 – 18:00	**Registration desk open**		
	5th Floor Pre-Function Space, Rydges Lakeland Resort		
08:30 – 12:30	**Innovation and impact workshop** (09:00 – 12:30)	**Pharmacogenomics workshop** (10:30 – 12:30)	**Clinical Pharmacology workshop - Matters of Dose** (08:30 – 12:30)
	Room: Clancy room, Rydges Lakeland Resort	**Room:** Dart room, QT Queenstown	**Room:** Rees room, QT Queenstown
	Chair: Prof Kevin Pfleger	**Chair:** Prof Andrew Somogyi	**Chair:** Dr Peter Donovan
	Accelerating Australia Supported by MTP Connect MedTech and Pharma Growth Centre **Why are innovation and impact important?** **How can they be achieved?** The workshop will include an introduction to SPARK by Prof Michael Wallach, Director, SPARK Oceania, as well as talks by SPARK Alumni SPARK Oceania	10:30 – 10:35 **Welcome and introduction** Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG 10:35 – 11:15 **Application of new tools to understand the genetics of adverse drug reactions** Prof Martin Kennedy, Carney Centre for Pharmacogenomics, University of Otago, New Zealand 11:15 – 11:40 **Precision medicine for type 2 diabetes** Assoc Prof Rinki Murphy, University of Auckland, New Zealand 11:40-12:15 **ECR/student short talks** **Common *CYP2D6*, *CYP2C9*, and *CYP2C19* gene variants, health anxiety and neuroticism are not strongly related to self-reported antidepressant side effects** Dr Simran Maggo, Carney Centre for Pharmacogenomics, University of Otago, New Zealand **Attitudes of healthy volunteers to genetic testing in phase I clinical trials** Mr Sebastian Levesque, Adelaide Medical School, University of Adelaide, Australia **Starting a new pharmacogenomics testing and reporting service in primary care in New Zealand with integration into practice software** Mr Sam Mostafa, My DNA Life, Australia 12:15-12:30 **Pharmacogenomics SIG AGM**	08:30 **Welcome and introduction** Assoc Prof Matt Doogue, University of Otago, Christchurch **Part 1 – The Principles of Dosing** 08:40 – 09:10 **Pharmacokinetic principles and dosing** Prof Evan Begg, University of Otago, Christchurch 09:10 – 09:40 **Choosing the dose** Prof Steve Duffull, School of Pharmacy, University of Otago 09:40 – 10:10 **Dosing patients today** Dr Phil Drennan, Royal Prince Alfred Hospital, University of Sydney 10:10 – 10:30 **Panel Discussion** 10:30 – 11:00 **Comfort break** **Part 2 – Going Beyond the Label** 11:00 – 12:30 **Group discussion to determine the "optimum" process to dose a selected medicine** 12:30 – 13:00 **Clinical Pharmacology SIG AGM**
12:30 – 13:30	**Break** (delegates to make their own lunch arrangements)		

13:30 – 16:30	**Education Forum—Shared our teaching ideas: Optimising pharmacology education to improve student outcomes**	**Neuropharmacology/Drug Discovery workshop**
	Room: Dart room, QT Queenstown	**Room:** Rees room, QT Queenstown
	Chairs: Lynette Fernandes and Anna-Marie Babey	**Chairs:** Wendy Imlach and Karen Gregory
	Adaptive e-tutorials Eryn Werry, The University of Sydney, Australia **Using Kahoot to engage students in tutorials** Zane Stromberga, Bond University, Australia **Using lightboards to convey pathways and signalling** Christian Moro, Bond University, Australia **Technology-enhanced learning in physiology and pharmacology: Virtual, augmented reality, gamification and holograms** Christian Moro, Bond University, Australia **Development of an ANKI card library for pharmacology foundation learning** Slade Matthews, The University of Sydney, Australia **Use of the online quizzing platform PeerWise in pharmacology education** Clare Guilding, Newcastle University Medicine Malaysia **The use of authentic, industry-focused learning activities to engage pharmacology students** Barb Kemp-Harper, Monash University, Australia **Discussion of issues in Pharmacology Education: Reimagining pharmacology practicals to large classes** **ASCEPT Education Forum AGM**	13:30 – 13:45 **New strategies to investigate the CCR2 signalling network using phosphoproteomics** Simon Foster, Monash University, Australia 13:45 – 14:00 **Low intrinsic G protein efficacy can explain the improved side effect profile of novel opioid ligands** Arisbel Batista-Gondin, Monash University, Australia 14:00 – 14:15 **Mechanistic insights into ligand-directed signalling bias as a class B G protein-coupled receptor – Characterisation of an adrenomedullin alanine library** Michael Garelja, University of Auckland, New Zealand 14:15 – 14:30 Comfort break 14:30 – 14:45 **BRET-based assays to study novel aspects of orexin receptor pharmacology** Natasha Dale, University of Western Australia, Australia 14:45 – 15:00 **Investigating the specificity of cannabidiol signalling** Shivani Sachdev, Macquarie University, Australia 15:00 – 15:15 **Identification of CXCL17 as a novel endogenous inhibitor of CXCR4** Carl White, University of Nottingham and Harry Perkins Institute of Medical Research, University of Western Australia, Australia 15:15 – 15:30 Comfort break 15:30 – 15:45 **Targeting spinal adenosine receptors to reduce pain signalling** India Cowie-Kent, Monash University, Australia 15:45 – 16:00 **Targeted delivery to the liver sinusoidal endothelium using orally administered silver sulfide quantum dots** Nick Hunt, The University of Sydney, Australia 16:00 – 16:15 **Investigating the role of the calcium-sensing receptor in airway contraction using mouse precision cut lung slices** Jiayin Diao, Monash University, Australia 16:15 – 16:23 Drug Discovery SIG AGM 16:23 – 16:30 Neuropharmacology SIG AGM
16:30 – 17:00	**Comfort break**	
17:00 – 18:00	**Conference opening and keynote address** **Room:** Coronet and Remarkables rooms, Rydges Lakeland Resort **Chairs:** Prof Carl Kirkpatrick and Assoc Prof David Foster **Wither mechanism-based modeling of drug action?** - 99 Prof Donald Mager, University of Buffalo, USA	Supported by ISOP International Society of Pharmacometrics
18:00 – 19:30	**Welcome reception** Reds Bar, Rydges Lakeland Resort	

University of Otago
Te Whare Wānanga o Otāgo
New Zealand
SAPERE AUDE

Division of Health Sciences
Te Wāhanga Matua Mātau Hauora

UNSW SYDNEY | Australia's Global University

UNSW Medicine

Postgraduate programs in pharmaceutical medicine

Advance your career in the pharmaceutical industry or make a career change by enrolling in a postgraduate degree in Pharmaceutical Medicine.

Delivered by UNSW Sydney – one of the world's top 50 universities – this is Australasia's leading postgraduate program in pharmaceutical medicine. It produces graduates with the knowledge and skills to make a meaningful contribution to medicines research, development and access, working across the pharmaceutical industry, academic health centres or government with the goal of improving the health and wellbeing of individuals.

For more information please visit
med.unsw.edu.au/pharmaceutical-medicine
or contact
pharm.med@unsw.edu.au

CRICOS Provider Code 00098G

CERTARA®

90+% of all novel drugs approved by the FDA were supported by Certara software and/or consulting services over the past 4 years.

Certara is the global leader in advancing modern, efficient drug development.

Learn how Certara can help you

Bb Bellberry Limited
supporting research and ethics

Join us... our core objective is to improve the welfare of research participants and the quality, efficiency and effectiveness of research in Australia.

Not for Profit

Independent & Streamlined
Science and Ethics Review

NHMRC-Certified
HREC meetings held weekly

Health & social science reviews

Study submission deadline
every Wednesday

Electronic application and review system

Full-time secretariat
providing support services

Independent site monitoring

Research Ethics Education

Call for more information or apply online

08 8361 3222
bellberry@bellberry.com.au
www.bellberry.com.au

Wednesday 27 November 2019

07:30 – 18:00	**Registration desk open**		
	5th Floor Pre-Function Space, Rydges Lakeland Resort		
08:00 - 08:45	**ASCEPT Rand Medal lecture**		Supported by THE UNIVERSITY OF MELBOURNE — School of Biomedical Sciences, Pharmacology and Therapeutics
	Room: Coronet and Remarkables rooms		
	Chair: Prof Carl Kirkpatrick		
	Molecular and structural basis of the allosteric control of GPCR phenotype by receptor activity-modifying proteins (RAMPs) - 100 Prof Patrick Sexton, Monash Institute of Pharmaceutical Sciences, Monash University		
09:00 - 10:30	**Oral presentations 1: Cardiovascular**	**Oral presentations 2: Pharmacoepidemiology**	**Oral presentations 3: Pharmacometrics and Clinical Pharmacology**
			Supported by CERTARA
	Room: Coronet room	**Room:** Von room, QT	**Room:** Remarkables room
	Chairs: Prof Rebecca Ritchie and Assoc Prof Chrishan Samuel	**Chairs:** Dr Jenni Ilomaki and Assoc Prof Bridin Murnion	**Chairs:** Assoc Prof David Foster and Dr Stefanie Hennig
09:00 – 09:15	**Both β1- and β2-adrenoceptors mediate arrhythmic contractions, ryanodine receptor channel opening and phosphorylation in human failing hearts: Control by PDE3** - 101 Assoc Prof Peter Molenaar, Queensland University of Technology, Australia	**Efficacy and safety of tapentadol immediate release for acute pain: A systematic review and meta-analysis** - 107 Miss Xinyi Wang, The University of Sydney, Australia	**A population pharmacokinetic model of mycophenolic acid using dual-phase absorption and plasma protein binding** - 113 Dr David Metz, The University of Melbourne, Australia

09:15 – 09:30	**Characterising prolonged high fat diet as a model of obesity-induced left ventricular diastolic dysfunction in mice** - 102 Dr Miles De Blasio, Baker Heart and Diabetes Institute, Australia	**Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review** - 108 Miss Marissa Sakiris, The University of Sydney, Australia	**A population pharmacokinetic model for metformin in patients receiving intermittent haemodialysis** - 114 Miss Klarissa Sinnappah, University of Otago, Dunedin, New Zealand
09:30 – 09:45	**Mechanisms underlying cognitive impairment during small vessel disease** - 103 Dr Michael De Silva, La Trobe University, Australia	**Missing data reporting in clinical pharmacy research** - 109 Dr Sujita Narayan, The University of Sydney, Australia	**External evaluation of published population pharmacokinetic models of tacrolimus in adult heart transplant recipients** - 115 Ms Ranita Kirubakaran, University of New South Wales, Australia
09:45 – 10:00	**Impact of diabetes on the murine cardiac cellular landscape and systemic leukocyte proportions** - 104 Mr Charles Cohen, Baker Heart and Diabetes Institute, Australia	**Pharmacological treatment dynamics in people initially prescribed metformin or sulfonylurea for type 2 diabetes** - 110 Mr Stephen Wood, Monash University, Australia	**Systematic literature review comparing target concentration intervention to therapeutic drug monitoring of vancomycin therapy** - 116 Mr Guangda Ma, The University of Auckland, New Zealand
10:00 – 10:15	**Effects of long-term polypharmacy and deprescribing on cardiovascular function and cardiac structure in aged mice** - 105 Ms Trang Tran, Kolling Institute of Medical Research, The University of Sydney, Australia	**Pharmacovigilance study of clozapine in New Zealand using three outcomes databases** - 111 Assoc Prof David Reith, University of Otago, New Zealand	**Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure** - 117 Dr Sophie Stocker, St Vincent's Hospital, Sydney, Australia
10:15 – 10:30	**Cardiomyocyte ErbB4 receptor deletion causes rapid-onset cardiac failure in neonatal mice** - 106 Dr Melissa Reichelt, The University of Queensland, Australia	**Recommendations of pharmacological alternatives for anticholinergic class of medications prescribed to individuals with dementia** - 112 Dr Sharmin Bala, University of Otago, New Zealand	**Regulatory Pharmacometrics in Australia** - 118 Dr Mahipal Sinnollareddy, Therapeutic Goods Administration, Australia
10:30 – 11:10	**Morning tea with exhibitors** **Poster presentations:** Clinical Pharmacology, Drug Discovery, Pharmacogenomics Supported by CARNEY CENTRE FOR PHARMACOGENOMICS		**Cardiovascular SIG AGM** **Room:** Coronet room **Toxicology SIG AGM** **Room:** Remarkables room
	5th Floor Pre-Function Space		
11:15 – 13:15	**Symposium 1: Novel pharmacotherapies for cardiopulmonary and respiratory diseases** Supported by Aus Bio Limited **Room:** Coronet room **Chairs:** Assoc Prof Barbara Kemp-Harper, Monash University and Prof Ross Vlahos, RMIT University, Australia	**Symposium 2: Innovative strategies to optimise medicine use in the older population to improve health outcomes** **Room:** Von room, QT **Chairs:** Dr Tom Polasek, Certara, Australia and Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	**Symposium 3: Molecular control of G protein-coupled receptor efficacy** Supported by ACS Pharmacology & Translational Science **Room:** Remarkables room **Chairs:** Prof Patrick Sexton, Monash University, Australia and Prof Debbie Hay, University of Auckland, New Zealand
11:15 – 11:45	**Optimising cyclic GMP signalling for the treatment of pulmonary hypertension** - 119 Prof Adrian Hobbs, William Harvey Research Institute, UK	**Complexity and clinical implications of multiple chronic conditions and polypharmacy in the older population** - 123 Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	**Proximal study of biased agonism at G protein-coupled receptors** - 127 Dr Peishen (Elva) Zhao, Monash University, Australia

11:45 – 12:15	**Pharmacological therapies to target reactivity and remodelling in cardiopulmonary disease** - 120 Dr Jane Bourke, Monash University, Australia	**A multi-country network to improve medicine use in people with Dementia: The NeuroGEN Collaboration** - 124 Dr Jenni Ilomaki, Monash University, Australia	**Unravelling the molecular basis of biased agonism using cryo-EM** - 128 Assoc Prof Denise Wootten, Monash University, Australia ThermoFisher SCIENTIFIC
12:15 – 12:45	**Novel therapeutic strategies for the treatment of chronic obstructive pulmonary disease** - 121 Assoc Prof Chrishan Samuel, Monash University, Australia	**Methodological challenges and innovative solutions: Understanding the complexity of pharmacoepidemiological studies in the older population** - 125 Prof Olaf Klungel, University of Utrecht, The Netherlands	**Structural basis for biased agonist action at the angiotensin II type 1 receptor** - 129 Dr Andrew Kruse, Harvard Medical School, USA Drug Discovery Biology MONASH University Institute of Pharmaceutical Sciences
12:45 – 13:15	**Improving immunotherapy response outcomes for lung cancer patients by developing novel biomarker assays** - 122 Prof Steven Bozinovski, RMIT University, Australia	**Clinical decision support tools for prescribing in the older population: From qualitative dashboards to quantitative modelling and simulation to enable precision dosing** - 126 Dr Tom Polasek, Certara, Australia	**Structural and functional insights into GPCR-beta-arrestin interaction and signaling** - 130 Dr Arun Shukla, Indian Institute of Technology, India
13:15 – 14:10	**Lunch with exhibitors** **Poster presentations:** Clinical Pharmacology, Drug Discovery, Pharmacogenomics		
	5th Floor Pre-Function Space		
14:15 - 15:45	**Oral presentations 4: Urogenital and Gastrointestinal**	**Oral presentations 5: Clinical Trainee and Clinical Pharmacology**	**Oral presentations 6: Drug Disposition and Response and Pharmacogenomics**
		Supported by AMH AUSTRALIAN MEDICINES HANDBOOK	Supported by University of South Australia
	Room: Coronet room	**Room:** Von room, QT	**Room:** Remarkables room
	Chairs: Dr Betty Exintaris and Dr Nick Veldhuis	**Chairs:** Dr Nicholas Farinola and Dr Amanda Gwee	**Chairs**: Dr Cornelia Landersdorfer and Dr Daniel Barratt
14:15 – 14:30	**Synthesis of novel P2X1-purinoceptor antagonists for use in male contraception** - 131 Dr Sab Ventura, Monash University, Australia	**Efficacy of endothelin receptor antagonists in patients with the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis** - 137 Dr Senthuran Shivakumar, Flinders Medical Centre, Australia	**Activity and potential biomarkers of evofosfamide in patient-derived and cell line xenograft models of head and neck cancer** - 143 Dr Stephen Jamieson, University of Auckland, New Zealand
14:30 – 14:45	**Exploring allosteric modulation of GPCRs for the treatment of gastrointestinal disorders** - 132 Dr Jesse DiCello, Monash University, Australia	**Use of cannabinoids to manage behaviour in children with developmental/behavioural disorders** - 138 Dr Angela Williams, The University of Queensland, Australia	**Effect of CYP2C19 phenotype and physiological differences on the pharmacokinetics of clopidogrel and its metabolites in European and Japanese populations** - 144 Dr Janna Duong, GlaxoSmithKline, Australia
14:45 – 15:00	**Purinergic P2X7 receptor inhibition protects urothelial cells from acrolein-induced cell death, which is independent of oxidative stress** - 133 Miss Zhinoos Taidi, UNSW, Australia	**Clinical outcomes and pharmacokinetic-pharmacodynamic target attainment in patients treated with oral flucloxacillin plus probenecid for staphylococcal infections** - 139 Dr Philip Drennan, Royal Prince Alfred Hospital, Australia	**ADME genes predict cancer patient survival: A comprehensive analysis of 21 different human cancers** - 145 Dr Dong Gui Hu, Flinders University, Australia

15:00 – 15:15	**Age-related changes in histamine receptor mediated contractions of the urinary bladder** - 134 Miss Zane Stromberga, Bond University, Australia	**Polypharmacy in palliative care: A retrospective comparison of two explicit deprescribing tools** - 140 Dr Richard McNeill, Canterbury District Health Board, Australia	**A model to inform in-vivo lignocaine pharmacokinetics from a controlled release device** - 146 Dr Jacqueline Hannam, University of Auckland, New Zealand
15:15 – 15:30	**The impact of ageing on urinary bladder muscarinic receptor activity** - 135 Assoc Prof Christian Moro, Bond University, Australia	**Monitoring for valproate toxicity in patients with hypoalbuminemia** - 141 Dr Arushi Madan, Royal Brisbane & Women's Hospital, Australia	**Assessment of inter-ethnic differences in imatinib dosing regimen using physiologically based pharmacokinetic (PBPK) modelling and simulation** - 147 Mr Jeffry Adiwidjaja, The University of Sydney, Australia
15:30 – 15:45	**Erianin induces apoptosis and autophagy in human prostate cancer cell** - 136 Mr I Gusti Surya C Trapika, The University of Sydney, Australia	**Medication adherence in gout: Identifying high-risk patient groups in an Australian clinical setting** - 142 Mr Chi Mao, University of New South Wales, Australia	**Molecular basis of the reduced enzyme activity associated with the cytochrome P450 2C9*3 (Ile359Leu) variant** - 148 Prof John Miners, Flinders University, Australia
15:45 – 16:10	**Afternoon tea with exhibitors** Supported by MONASH University | MONASH BIOMEDICINE DISCOVERY INSTITUTE 5th Floor Pre-Function Space		**Inflammation/Respiratory SIG AGM** **Room:** Von room, QT **Drug Disposition and Response SIG AGM** **Room:** Remarkables room
16:15 – 18:15	**Certara New Investigator Award** **Room:** Coronet and Remarkables rooms **Chair:** Prof Carl Kirkpatrick		Supported by CERTARA
16:15 – 16:45	**Discovery of novel peptide ligands for orphan G protein-coupled receptors** - 149 Dr Simon Foster, Monash University, Australia		
16:45 – 17:15	**The roles of aerosolized polymyxins in the treatment of lung infections: A step towards dose optimisation** - 150 Dr Yu-Wei (Wayne) Lin, Monash University, Australia		
17:15 – 17:45	**Translational toxicovigilance: Preventing drug related harms through legislation and policy** - 151 Dr Rose Cairns, The University of Sydney, Australia		
17:45 – 18:15	**Gain from pain: Using venomous animals to explore new nociceptive pathways** - 152 Dr Samuel Robinson, The University of Queensland, Australia		
18:15 – 18:45	**ASCEPT New Zealand AGM** **Room:** Von room, QT		

THE UNIVERSITY OF AUCKLAND
Te Whare Wānanga o Tāmaki Makaurau
NEW ZEALAND

MEDICAL AND HEALTH SCIENCES
SCHOOL OF MEDICAL SCIENCES

Pharmacy and Pharmacology, University of Auckland - ranked #30 in the world QS World University rankings

douglas
improving lives

An award-winning
NZ pharmaceutical company
focused on making a positive
difference in healthcare.

douglas.co.nz

UNSW SYDNEY
Australia's Global University

UNSW Medicine
St Vincent's Clinical School

The Clinical Pharmacology and Toxicology Department, part of St Vincent's Clinical School UNSW Sydney, was established by Denis Wade in 1970.

We provide leadership in clinical pharmacology, toxicology, therapeutics and quality use of medicines locally, nationally and internationally through our research, teaching and training, advisory roles and collaborations.

We focus on understanding inter-subject variation in response to medicines through high quality clinical research.

Come and join us!
stvcs.med.unsw.edu.au/clinical-pharmacology

CRICOS Provider Code 00098G

MONASH University

Monash Institute of Pharmaceutical Sciences

- Drug Discovery Biology
- Medicinal Chemistry
- Drug Candidate Optimisation
- Drug Delivery Disposition and Dynamics
- Medicine Use and Safety

Proud sponsor of ASCEPT-PAGANZ 2019

ASCEPT PAGANZ
Population Approach Group of Australia & New Zealand
AMH
AUSTRALIAN MEDICINES HANDBOOK

AMH is honoured to attend the ASCEPT-PAGANZ 2019 Joint Scientific Meeting and supports the core objective of optimising drug response to improve patient outcomes.

www.amh.net.au

Thursday 28 November 2019

07:30 – 17:00	**Registration desk open** 5th Floor Pre-Function Space		
08:00 – 09:30	**Oral presentations 7: Inflammation / Respiratory** **Room:** Coronet room **Chairs:** Assoc Prof Stavros Selemidis and Dr Simone De Luca	**Oral presentations 8: Drug Discovery** **Room:** Von room, QT **Chairs:** Assoc Prof Denise Wootten and Dr Jesse DiCello	**Oral presentations 9: Clinical Pharmacology** **Room:** Remarkables room **Chairs**: Assoc Prof Matt Doogue and Dr Catherine Lucas
08:00 – 08:15	**Comparison of two mice models of non-alcoholic steatohepatitis** - 200 Ms Cheng Peng, The University of Melbourne, Australia	**Identification of CXCL17 as an endogenous inhibitor of CXCR4** - 206 Dr Carl White, University of Nottingham, UK; University of Western Australia, Australia	**Proteomic analysis of drug metabolising enzymes in extracellular vesicles as potential biomarkers** - 212 Dr Madelé van Dyk, Flinders University, Australia
08:15 – 08:30	**The role of Transforming Growth Factor β (TGFβ) in the response to Influenza A viral infection** - 201 Miss Julia Chitty, Monash University, Australia	**One inhibitor, two mechanisms? Evidence for allosteric regulation of the lipid kinase PI3Kalpha** - 207 Dr Jack Flanagan, University of Auckland, New Zealand	**Determining the pre-analytical instability of beta-Lactam antibiotics in therapeutic drug monitoring samples** - 213 Miss Janni Mortensen, University of Copenhagen, Denmark
08:30 – 08:45	**A fresh look at cGMP in innate immune responses** - 202 Prof Helen Irving, La Trobe University, Australia	**Investigating the role of the calcium-sensing receptor in airway contraction using mouse precision cut lung slices** - 208 Miss Jiayin Diao, Monash University, Australia	**Efficacy and Safety of opioid analgesics for acute pain conditions: An overview of systematic reviews** - 214 Dr Christina Abdel Shaheed, Institute for Musculoskeletal Health; The University of Sydney, Australia
08:45 – 09:00	**Effects of prolonged exposure to paracetamol on late gestation rat placenta** - 203 Miss Yifan Huang, The University of Melbourne, Australia	**New strategies to investigate the CC Chemokine Receptor 2 (CCR2) signalling network using phosphoproteomics** - 209 Dr Simon Foster, Monash University, Australia	**Inability of current dosing to achieve carboplatin targets in advanced NSCLC: Impact of systemic inflammation on carboplatin PK and outcomes** - 215 Assoc Prof Kellie Charles, The University of Sydney, Australia
09:00 – 09:15	**Mediators from silica-treated macrophages influence contraction of collagen gels seeded with human lung fibroblasts** - 204 Ms Claudia Sim, Biomedicine Discovery Institute; Monash University, Australia	**Low intrinsic G protein efficacy can explain the improved side effect profile of novel opioid ligands** - 210 Dr Arisbel Batista Gondin, Monash University, Australia	**Economic evidence for deprescribing medications: A systematic review** - 216 Mr Alexander Clough, The University of Sydney, Australia
09:15 – 09:30	**In vivo LPS exposure differentially alters intrapulmonary artery reactivity in mouse precision cut lung slices** - 205 Miss Emma Lamanna, Monash University, Australia	**Orai channel alterations as a consequence of differentiation in a human neural progenitor cell line** - 211 Ms Silke Chalmers, The University of Queensland, Australia	**Substance use in patients with dual diagnosis** - 217 Dr David Taylor, Eastern Health, Australia
09:45 – 10:15	**Early Achievement Award for Women** **Room:** Coronet and Remarkables rooms **Chair:** Dr Danijela Gnjidic **Mechanistic Insights into the Synergistic Antibacterial Effect of a Polymyxin B - ivacaftor combination Against Cystic Fibrosis Pseudomonas aeruginosa** - 218 Dr Elena Schneider-Futschik, The University of Melbourne, Australia		
10:15 – 10:30	**ASCEPT launch of Equity, Diversity and Inclusion Policy** **Room:** Coronet and Remarkables rooms		
10:30 – 10:40	**Launch morning tea**		
10:40 – 11:10	**Morning tea with exhibitors** **Poster presentations:** Cardiovascular, Drug Disposition and Response, Toxicology, Neuro- and Behavioural Pharmacology, Education, Inflammation/Respiratory, Pharmacoepidemiology, Urogenital and Gastrointestinal 5th Floor Pre-Function Space		

11:15 – 13:15	**Symposium 4: SGLT2 inhibitors: How good are they really?**	**Symposium 5: Precision medicine in oncology: Beyond diagnosis**	**Symposium 6: Drug dosing in children – how to do it better!**
		Supported by THE UNIVERSITY OF AUCKLAND NEW ZEALAND MEDICAL AND HEALTH SCIENCES SCHOOL OF MEDICAL SCIENCES	Supported by UNIVERSITY OF OTAGO Division of Health Sciences *Te Wāhanga Matua Mātau Hauora*
	Room: Coronet room	**Room:** Von room, QT	**Room:** Remarkables room
	Chairs: Dr Jenni Ilomaki, Monash University, Australia and Assoc Prof Matt Doogue, University of Otago, New Zealand	**Chairs:** Prof Andrew Somogyi, University of Adelaide, Australia and Dr Cornelia Landersdorfer, Monash University, Australia	**Chairs:** Assoc Prof Noel Cranswick, Royal Children's Hospital, The University of Melbourne, Australia and Prof Jennifer Martin, The University of Newcastle, Australia
11:15 – 11:45	**SGLT2 inhibitors: Evidence from observational studies** - 219 Prof Olaf Klungel, Utrecht University, The Netherlands	**Precision medicine in lung cancer treatment** - 223 Prof Mark McKeage, University of Auckland, New Zealand	**The principles of dosing, response variability, and dose individualisation challenges in children** - 227 Dr Hesham Al-Sallami, University of Otago, New Zealand
11:45 – 12:15	**SGLT2 inhibitors: Evidence from RCTs** - 220 Dr Ingrid Hopper, Monash University, Australia	**Establishment of a therapeutic drug monitoring programme for the treatment of childhood cancer patients in the UK** - 224 Prof Gareth Veal, Newcastle University, UK	**Dosing antibiotics: Method development in neonates** - 228 Dr Amanda Gwee, Royal Children's Hospital, Australia
12:15 – 12:45	**Emerging adverse drug reactions related to SGLT2 inhibitors** - 221 Dr Jenni Ilomaki, Monash University, Australia	**Comparison of target concentration intervention dosing tools for busulfan in children** - 225 Dr Stefanie Hennig, The University of Queensland, Australia	**Immunosuppressant dosing in children: Learning from children and adults** - 229 Dr David Metz, Royal Children's Hospital, Australia
12:45 – 13:15	**SGLT2 inhibitors in clinical practice** - 222 Assoc Prof Matt Doogue, University of Otago, New Zealand	**Predicting severe life-threatening toxicity after fluoropyrimidine drugs** - 226 Assoc Prof Nuala Helsby, University of Auckland, New Zealand	**Predicting time required for complete drug elimination of Infliximab and Adalimumab from infants exposed in utero: A Bayesian forecasting method** - 230 Dr Zheng Liu, University of Newcastle, Australia
13:15 – 14:10	**Lunch with exhibitors** **Poster presentations:** Cardiovascular, Drug Disposition and Response, Toxicology, Neuro- and Behavioural Pharmacology, Education, Inflammation/Respiratory, Pharmacoepidemiology, Urogenital and Gastrointestinal		Supported by NEUROSolutions LTD.
	5th Floor Pre-Function Space		
14:15 – 15:45	**Oral presentations 10: Neuro- and Behavioural Pharmacology and Drug Discovery**	**Oral presentations 11: Education and Toxicology**	**Oral presentations 12: ASCEPT Garth McQueen Prize**
	Room: Coronet room	**Room:** Von room, QT	**Room:** Remarkables room
	Chairs: Dr Eryn Werry and Dr Martina Kocan	**Chairs:** Dr Ian Musgrave and Dr Slade Matthews	**Chairs**: Dr Wendy Imlach and Dr Jane Carland
14:15 – 14:30	**Investigating the effects of OxR1 antagonism on goal-directed decision making** - 231 Mr Jeremy Metha, The University of Melbourne, Australia	**Responding the WHO 3rd global patient safety challenge: Development of an inter-professional medication safety education programme** - 237 Assoc Prof Kellie Charles, The University of Sydney, Australia	**Targeting the NLRP3 inflammasome as a novel approach to treat pulmonary hypertension** - 243 Mrs Tara Scott, Monash University, Australia

14:30 – 14:45	**An evaluation of timed snapshot signalling bias analyses for non-equilibrium systems** - 232 Mr Xiao Zhu, University of Otago, New Zealand	**The third iteration of a foundational unit in a new Pharmacy curriculum** - 238 Dr Betty Exintaris, Monash University, Australia	**Influenza A virus provokes maternal vascular dysfunction, inflammation and intrauterine growth restriction** - 244 Mr Osezua Oseghale, RMIT University, Australia
14:45 – 15:00	**Cigarette smoking cessation does not reverse hippocampal-dependent cognitive impairment in mice** - 233 Dr Simone De Luca, RMIT University, Australia	**Multiple choice questions: Can they assess application of knowledge in pharmacology teaching** - 239 Dr Suong Ngo, The University of Adelaide, Australia	**Real-world efficacy and safety outcomes of imatinib treatment in patients with Chronic Myeloid Leukemia: An Australian experience** - 245 Miss Josephine Touma, The University of Sydney, Australia
15:00 – 15:15	**Investigation of the specificity of cannabidiol signalling** Miss Shivani Sachdev, Macquarie University, Australia	**Developing techniques to isolate and characterise individual Russell's viper venom peptides and proteins** - 240 Ms Rachael Thomas, University of South Australia, Australia	**Identifying and prioritising patients at high-risk of medication harm using risk prediction models** - 246 Mrs Nazanin Falconer, The University of Queensland, Australia
15:15 – 15:30	**Idiosyncratic effects of vigabatrin result from gain-of-function GABAA variants** - 235 Prof Mary Chebib, The University of Sydney, Australia	**The in vitro neurotoxicity of Indian cobra (Naja naja) venom: Efficacy of antivenom** - 241 Mr Tam Huynh, Monash University, Australia	**The M2 macrophage-derived chemokine, CCL18 is elevated in hypertension and promotes vascular fibrosis** - 247 Miss Mingyu Zhu, Monash University, Australia
15:30 – 15:45	**The in vitro biological effects of Cannabichromene enantiomers and analogues** - 236 Dr Marina Junqueira Santiago, Macquarie University, Australia	**Multitask deep learning for metabolism-aware strain-specific assessment of Ames mutagenicity** - 242 Mr Raymond Lui, The University of Sydney, Australia	**Chronic cigarette smoke exposure causes cognitive impairment and neuroinflammation in mice** - 248 Mr Aleksandar Dobric, RMIT University, Australia
15:45 – 16:10	**Afternoon tea with exhibitors** 5th Floor Pre-Function Space		**Pharmacoepidemiology SIG AGM** **Room:** Von room, QT
16:15 – 17:15	**Japanese Pharmacological Society keynote address** **Room:** Coronet and Remarkables rooms **Chair:** Prof Carl Kirkpatrick **Mesoscopic approaches for brain networks: Pharmaceutical and electroceutical insights** - 249 Prof Yuji Ikegaya, The University of Tokyo, Japan		Supported by Bellberry Limited supporting research and ethics
17:15 – 18:15	**ASCEPT AGM** **Room:** Coronet and Remarkables rooms		
19:00 – 23:30	**Meeting dinner** Skyline Queenstown		Supported by douglas improving lives

Friday 29 November 2019

08:00 – 12:30	**Registration desk open** 5th Floor Pre-Function Space		
08:30 – 09:30	**British Pharmacological Society keynote address** **Room:** Coronet and Remarkables rooms **Chair:** Prof Carl Kirkpatrick **PBPK-IVIVE: The Trojan Horse that Re-injected Mechanisms Back into Models** - 300 Prof Amin Rostami-Hodjegan, University of Manchester, UK		Supported by THE UNIVERSITY OF SYDNEY
09:30 – 10:25	**Morning tea with exhibitors** **Student poster finalists presentations** 5th Floor Pre-Function Space		Supported by ASPET Transforming Discoveries into Therapies
10:30 – 12:30	**Symposium 7: Gout: Moving towards centre stage** Supported by St Vincent's Clinical School UNSW SYDNEY **Room:** Coronet room **Chairs:** Prof Richard Day and Dr Sophie Stocker, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	**Symposium 8: Novel therapies for the treatment of stroke and neurological disorders** **Room:** Von room, QT **Chairs:** Dr Michael De Silva, La Trobe University, Australia and Dr Simon Foster, Monash University, Australia	**Symposium 9: Using simulation as a learning tool to develop work place readiness** **Room:** Remarkables room **Chairs:** Dr Hesham Al-Sallami, University of Otago, New Zealand and Associate Prof Lynette Fernandes, University of Western Australia, Australia
10:30 – 11:00	**Allopurinol at the coal face – can we really get to target with an old drug?** - 301 Prof Lisa Stamp, University of Otago, New Zealand	**Amnion epithelial cell therapy for stroke: Translation of experimental findings into a Phase I clinical trial** - 305 Prof Chris Sobey, La Trobe University, Australia	**Using patient simulation in the lecture theatre to introduce "real-life" scenarios** - 309 Dr Clare Guilding, Newcastle University Medicine, Malaysia
11:00 – 11:30	**Model-based dosing in patients with gout: The curious case of allopurinol** - 302 Dr Daniel Wright, University of Otago, New Zealand	**Tailoring metabotropic glutamate receptor 5 activity with biased allosteric modulators for neurodegenerative disorders** - 306 Dr Karen Gregory, Monash University, Australia	**Using simulations to develop proficiency in the application of pharmacokinetic concepts** - 310 Dr Cornelia Landersdorfer and Dr David Shackleford, Monash University, Australia
11:30 – 12:00	**Off indication medicines and novel strategies with potential to treat gout** - 303 Prof Anthony Rodgers, UNSW Sydney, The George Institute for Global Health, UNSW Medicine, Australia	**The delta-subunit selective GABAA receptor modulator, DS2, improves stroke recovery via an anti-inflammatory mechanism** - 307 Dr Andrew Clarkson, University of Otago, New Zealand	**Clinical Pharmacology Top Trumps for the gamification of student learning about medicines** - 311 Assoc Prof Matt Doogue, Christchurch Hospital and University of Otago, New Zealand
12:00 – 12:30	**Strategies to improve outcomes for people with gout: eMed approaches** - 304 Prof Richard Day, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	**Molecular pharmacology of Cannabinoid Receptor 2, a promising immunomodulatory target** - 308 Dr Natasha Grimsey, University of Auckland, New Zealand	**Real-time simulation to help students become more confident and reflective practitioners** - 312 Prof Steve Duffull, Otago University, New Zealand **Panel discussion**
12:45 – 13:15	**Awards and meeting close** **Room:** Coronet and Remarkables rooms **Chair:** Dr Danijela Gnjidic		
13:15 – 13:45	**Lunch** 5th Floor Pre-Function Space		

NEUROSolutions LTD.

Focusing on technical excellence, complete confidentiality, protocol flexibility and the rapid production of your data

NeuroSolutions Ltd, established in 2001 by Professor David Spanswick is a contract research organisation providing electrophysiological and behavioural research in the field of neuroscience.

Our highly qualified team of scientists deliver preclinical research solutions from the single cell right through to the whole animal tailored precisely to our client's needs.

We work on single fee-for-service contracts right up to multiple member research teams driving forward development programs under FTE agreements or as a working partnership. We incorporate the latest technologies in our pursuit of electrophysiological excellence, providing animal behavioural and molecular biological services of the highest quality in parallel with our electrophysiological expertise.

Find out about the diverse range of bespoke assays NeuroSolutions offers in supporting drug discovery and development **www.nsolns.com**

IN PARTNERSHIP WITH PACIFIC DISCOVERY SERVICES

Cerebrasol

NeuroSolutions Ltd., **Company Number** 04199343
PO Box 3517, Coventry, CV4 7ZS, U.K.
Tel: +44 (0)8454 500 171 **Email:** info@nsolns.com **Web:** www.nsolns.com

Thank you to our sponsors

Major meeting sponsors

Bellberry Limited
supporting research and ethics

THE UNIVERSITY OF SYDNEY

CERTARA

THE UNIVERSITY OF MELBOURNE
School of Biomedical Sciences
Pharmacology and Therapeutics

Key meeting sponsors

THE UNIVERSITY OF AUCKLAND
MEDICAL AND HEALTH SCIENCES
SCHOOL OF MEDICAL SCIENCES

UNSW SYDNEY

NEUROSolutions LTD.

UNIVERSITY of OTAGO
Division of Health Sciences
Te Wāhanga Matua Mātau Hauora

University of South Australia

AMH
AUSTRALIAN MEDICINES HANDBOOK

MONASH University
Institute of Pharmaceutical Sciences

Speaker sponsors

Aus Bio Limited

ISOP
INTERNATIONAL SOCIETY OF PHARMACOMETRICS

ACS Pharmacology & Translational Science

Drug Discovery Biology

ThermoFisher SCIENTIFIC

Meeting contributors

UNIVERSITY of OTAGO
School of Pharmacy
Te Kura Mātauraka Wai - whakaora

AFT pharmaceuticals
Working to improve your health

PKPDRX

Meeting supporters

MONASH University
MONASH BIOMEDICINE DISCOVERY INSTITUTE

CARNEY CENTRE FOR PHARMACOGENOMICS

ASPET
Transforming Discoveries into Therapies

Dinner sponsor

douglas
improving lives

Exhibitors only

APAC SCIENTIFIC

AD INSTRUMENTS
making science easier

TRAJAN

Conference secretariat

expert events
Professional conference organiser

T: +61 7 3848 2100 I E: ascept-paganz@expertevents.com.au
PO Box 351, Hamilton Central, QLD 4007 Australia